Fintepla
What Fintepla is used for
Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Fintepla
- Active substance
- fenfluramine
- Disease area
- Epilepsies, Myoclonic
- Medicine group
- Antiepileptics
- ATC code
- N03
- Marketing authorisation holder
- UCB Pharma S.A.
- Authorised in the EU since
- 2020
Official information
In India
- Fenfluramine hydrochloride: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Fintepla used for?
Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
What is the active substance in Fintepla?
Fintepla contains fenfluramine.
Who makes Fintepla?
The EU marketing authorisation holder is UCB Pharma S.A..
Is Fintepla an orphan medicine?
Yes. Fintepla is designated an orphan medicine in the EU, for a rare disease (Epilepsies, Myoclonic).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU